Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2026 08:00 ET | Source: Novo Nordisk A/S

Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

Novo Nordisk and Vivtex Corp announced partnership to develop next-generation oral biologic medicines for obesity, diabetes + associated comorbidities
February 24, 2026 03:39 ET | Source: Novo Nordisk A/S

Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

The United Laboratories International Holdings Limited and Novo Nordisk today announced topline results from a Chinese phase 2 trial of UBT251
February 23, 2026 07:24 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 23 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
February 23, 2026 04:33 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved

CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84...
February 20, 2026 07:02 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 20 February 2026 – The Annual General Meeting will be held on: Thursday 26 March 2026 at 14:00 (CET) The Annual General Meeting will be held as a combined physical and virtual...
February 17, 2026 08:58 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average

Final EU approval of high-maintenance dose of Wegovy. The new dose gives healthcare professionals even more flexibility to tailor treatment.
February 16, 2026 07:21 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 16 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
February 11, 2026 15:14 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 11 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
February 10, 2026 04:17 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 10 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
February 09, 2026 07:16 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 9 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...